Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT05927142 |
| Title | Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy (DURIPANC) |
| Acronym | DURIPANC |
| Recruitment | Recruiting |
| Gender | both |
| Phase | Phase Ib/II |
| Variant Requirements | No |
| Sponsors | Joachim Aerts, MD PhD |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | NLD |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Erasmus MC | RECRUITING | Rotterdam | Zuid-Holland | 3000 CA | Netherlands | Details |